Background paper 11
The Independent Panel for Pandemic Preparedness and Response
May 2021
Tuberculosis (TB) is, and should be, a curable disease; however, each year significant numbers of patients acquire or develop drug-resistant TB, which has a much lower cure rate. Patients with drug-resistant TB have a high prevalence of symptoms; hence, staff caring for these patients should h...ave some familiarity with palliative care, so that general palliative care principles are available to all patients. The timely identification, and addressing, of adverse events occurring during the treatment course is considered as general palliative care for those receiving curative treatment. This publication summarizes the general palliative care approach, which is recommended for use in settings and services that occasionally treat palliative care patients, but do not provide palliative care as the main focus of their work. The review focuses on 18 high TB priority countries of the WHO European Region.
more
10 May 2021
This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020.
This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considera...tions on vaccine certificates or “passports” will be covered in an update of WHO interim guidance, as requested by the COVID-19 emergency committee.
more
Updated 8 June 2021. Coronavirus is spreading globally. How can individuals, communities, humanitarian actors, local and national authorities best respond to uphold the rights of all affected people?
El documento “Preguntas y respuestas sobre la tuberculosis” provee
información sobre el diagnóstico y el tratamiento de la infección de
tuberculosis y de la enfermedad de tuberculosis. Las audiencias principales
para este material informativo son las personas con TB o en riesgo de
contrae...r TB.
more
La miocarditis es una enfermedad inflamatoria con compromiso focal o difuso del miocardio, que se presenta de forma fulminante, pudiendo ser aguda, subaguda o crónica.Las que poseen un nivel de gravedad suficiente para reconocerlas clínicamente, son raras, pero la prevalencia de los casos leves y ...asintomáticos probablemente sea más elevada.
more
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed
to support decision making. A countrywide mass vaccination campaign with the
use of an inactivated severe acute respiratory syndrome c...oronavirus 2 (SARS-CoV-2)
vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.
more
Projects from around the world
Joule 5, 2687–2714 October 20, 2021 Cell Press
Waste Management & Research 39(1) DOI: 10.1177/0734242X211029175
The document is structured into five sections. The first presents the key experiences and challenges that justify a renewal of the EPHFs. The second section updates the groundwork for the exercise of public health and provides a framework to inform the exercise of the new essential functions. The th...ird section proposes a new integrated approach for implementing the EPHFs. The fourth section presents a new list of 11 EPHFs related to each stage of this integrated approach. Finally, in the last section, considerations are put forth to guide EPHF implementation as a means of strengthening the health sector.
more
Orientación para las Sociedades Nacionales de las Américas
Orientations provisoires, 1er février 2021
La recherche des contacts – associée à un dépistage rigoureux, à l’isolement et à la prise en charge des cas – est une stratégie clé pour interrompre les chaînes de transmission du SRAS-CoV-2 et réduire la mortalité associée... à la COVID-19.
more
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
Orientations provisoires, 28 janvier 2021
Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... sécurité biologique relatifs à la réalisation des tests diagnostiques rapides antigéniques, manipulation des nouveaux variants du SARS-CoV-2 au laboratoire, mise à jour de la décontamination des tests avant leur élimination, équipement de protection individuelle (EPI) pour le prélèvement d’échantillons et, même s’ils ne concernent pas directement la sécurité biologique, dangers chimiques et leur élimination en toute sécurité.
more